Hoth Therapeutics’ (HOTH) “Buy” Rating Reiterated at D. Boral Capital

D. Boral Capital reissued their buy rating on shares of Hoth Therapeutics (NASDAQ:HOTH) in a research note issued to investors on Tuesday,Benzinga reports. D. Boral Capital currently has a $5.00 target price on the stock.

Several other brokerages also recently issued reports on HOTH. HC Wainwright reiterated a “buy” rating and issued a $4.00 price target on shares of Hoth Therapeutics in a report on Monday, November 4th. Benchmark reiterated a “speculative buy” rating and issued a $3.00 target price on shares of Hoth Therapeutics in a research note on Friday, October 11th.

Hoth Therapeutics Price Performance

Hoth Therapeutics stock opened at $1.90 on Tuesday. The company has a market cap of $13.12 million, a price-to-earnings ratio of -1.44 and a beta of 0.75. Hoth Therapeutics has a 12 month low of $0.58 and a 12 month high of $3.80. The stock’s 50-day moving average is $0.88 and its 200-day moving average is $0.86.

Hoth Therapeutics (NASDAQ:HOTH) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.31) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.01). Research analysts anticipate that Hoth Therapeutics will post -1.18 EPS for the current year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Hoth Therapeutics stock. Virtu Financial LLC bought a new stake in Hoth Therapeutics, Inc. (NASDAQ:HOTH) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 32,636 shares of the company’s stock, valued at approximately $29,000. Virtu Financial LLC owned approximately 0.47% of Hoth Therapeutics as of its most recent SEC filing. 7.08% of the stock is owned by institutional investors and hedge funds.

About Hoth Therapeutics

Hoth Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19.